# Capital Grand Est

> Capital Grand Est is a VC fund backing Health Care and Biotechnology. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Schiltigheim, France
- Total investments: 16
- Last investment: Oct 2025
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/capitalgrandest/
- Website: https://www.capitalgrandest.eu/

Capital Grand Est is a private equity firm that focuses on supporting businesses. Capital Grand Est was founded in 2012 and was headquartered in Schiltigheim, France.

## Contacts

5 contacts available for Capital Grand Est. Shizune tracks 1 team members at Capital Grand Est. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/capital-grand-est?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.1M–$13M |
| Series A | $2.6M–$19M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 38% |
| Biotechnology | 5 | 31% |
| Medical Device | 4 | 25% |
| Medical | 3 | 19% |
| Manufacturing | 3 | 19% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 31% |
| Series A | 5 | 31% |
| Funding Round | 4 | 25% |
| Venture - Series Unknown | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Stéphane BECKER | Director of Investments | 0 | https://shizune.co/investors/profile/stphane-becker |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EVerZom | EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellularvesicles that encompass exosomes, microvesicles, and apoptotic bodies are the tools used by cells to communicate with each other. EVerZom was founded in 2019 and is headquartered in Paris, Ile-de-France, France. | $11.6M | Series A | Oct 14, 2025 |  |
| RDS | RDS is a healthcare technology startup that specializes in remote patient monitoring solutions. The company's primary product, MultiSense®, is designed to help healthcare professionals continuously monitor patients' physiological parameters, whether they're in a hospital or at home. This innovative and multi-patented technology isaimed at improving patient pathways, which in turn enhances the quality of life and care efficiencies. The company's market is primarily hospitals (particularly surgical departments) and institutions that are looking for ways to improve patient care and reduce hospital stays. By facilitating early hospital discharge and continuous monitoring, RDS solution can contribute to significant healthcare savings. The MultiSense® solution is now CE marked (MDR) and is available for sale in several European countries. The company generates recurring revenues by providing the solution on a “fee for a service” business model to healthcare institutions and professionals. The product has been well-received in the market, earning multiple awards and the support of a vibrant community of clinicians. In addition to its primary product, RDS also provides services that help healthcare systems become more attractive and sustainable. This includes training and support for healthcare professionals to effectively use the MultiSense® technology. Keywords: Healthcare Technology, Remote Patient Monitoring, MultiSense®, Patient Pathways, Care Efficiencies, Hospital Discharge, Healthcare Savings, Clinicians, Physiological Parameters, Our main product, MultiSense®, is a comprehensive Remote Patient Monitoring Solution. MultiSense® offers healthcare professionals a high-precision, multi-parametric solution to continuously monitor patients’ physiological parameters in the hospital and beyond. MultiSense® combines a wearable patient monitor designed to capture high-accuracy physiological data with a cloud platform that helps transform these data into actionable clinical insights. MultiSense® is a patented medical device that has received multiple awards. MultiSense® has been validated by 6 completed clinical investigations.RDS relies on a talented and international team with deep subject-matter-expertise and a proven track record in the Healthcare and Medical Device sector. At RDS, we all share the same passion for bringing patient pathways to the next level. | $16.4M | Series A | Sep 29, 2025 |  |
| Dianosic | Dianosic was founded in 2017 and develops innovative solutions in the field of ENT (Ear, Nose & Throat), a $50 billion, double digit growth, and still largely underserved market. Our startup operates right at the frontier between Medtech and Biotech, as we see tremendous opportunities for drug-device combinations in this specialty. The projectoriginates from the ENT Department from the University Hospital of Strasbourg, where unmet clinical needs have been identified. Our main focus areas are Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis). Noteworthy, Dianosic has a strong French and German footprint in R&D and manufacturing.Dianosic’s strategic goal is to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This drug-device combination ARIS platform, developed with world renowned resorbable polymers experts, has the potential to establish new treatment paradigms. Moreover, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.Beside this, Dianosic commercialize an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, a widespread condition in ENT that affects 10% of the population. This CE marked and FDA registered technology addresses a clear unmet need and demonstrated our ability not only to develop a differentiated technology in record time, but also to successfully transition from R&D to Sales. We are currently present in relevant markets in EU and paving the way to launch in the U.S. in the mid term. Noteworthy, since our main call point is the ENT, CAVI-T prepares the ground for our upcoming ARIS platform. | $8.2M |  | Sep 05, 2025 |  |
| Elkedonia | Elkedonia is a biotech company dedicated to transforming antidepressant therapy. It aims to develop a groundbreaking antidepressant treatment that is accessible, fast-acting, and free from the risks of dependence, sedation, or psychotic effects. | $12.9M | Seed | Jun 11, 2025 |  |
| Sounduct | Sounduct is a medical equipment manufacturer. | $3.4M | Seed | Jun 03, 2025 |  |
| SUPERBRANCHE | SUPERBRANCHE is a biotechnology company for the early detection and treatment of metastases through nanotechnological provisions. | $13.5M |  | Feb 04, 2025 |  |
| Keey Aerogel | Keey Aerogel is the exclusive manufacturer of silica aerogel produced from construction waste through a closed-loop process that recycles carbon dioxide and ethanol. | $18.8M | Series A | Jan 28, 2025 |  |
| Cixten | Cixten is a company that recycles low temperature waste heat into other energy vectors by leveraging the features of supercritical CO2. | $2.6M | Seed | Sep 15, 2024 |  |
| Sirfull Technology | Sirfull Technology offers innovative software solutions dedicated to industrial assets management.The company specializes in developing welding quality and equipment life cycle management cloud software and offers software to manage welding quality control and technical documentation as well as an equipment inspection software that collaborates theinspection, monitoring, and risk management of industrial equipment to centralize in a collaborative platform, enabling its clients to optimize their business processes through digital manufacturing services. | $6.6M | Venture - Series Unknown | Sep 02, 2024 |  |
| RDS | RDS is a healthcare technology startup that specializes in remote patient monitoring solutions. The company's primary product, MultiSense®, is designed to help healthcare professionals continuously monitor patients' physiological parameters, whether they're in a hospital or at home. This innovative and multi-patented technology isaimed at improving patient pathways, which in turn enhances the quality of life and care efficiencies. The company's market is primarily hospitals (particularly surgical departments) and institutions that are looking for ways to improve patient care and reduce hospital stays. By facilitating early hospital discharge and continuous monitoring, RDS solution can contribute to significant healthcare savings. The MultiSense® solution is now CE marked (MDR) and is available for sale in several European countries. The company generates recurring revenues by providing the solution on a “fee for a service” business model to healthcare institutions and professionals. The product has been well-received in the market, earning multiple awards and the support of a vibrant community of clinicians. In addition to its primary product, RDS also provides services that help healthcare systems become more attractive and sustainable. This includes training and support for healthcare professionals to effectively use the MultiSense® technology. Keywords: Healthcare Technology, Remote Patient Monitoring, MultiSense®, Patient Pathways, Care Efficiencies, Hospital Discharge, Healthcare Savings, Clinicians, Physiological Parameters, Our main product, MultiSense®, is a comprehensive Remote Patient Monitoring Solution. MultiSense® offers healthcare professionals a high-precision, multi-parametric solution to continuously monitor patients’ physiological parameters in the hospital and beyond. MultiSense® combines a wearable patient monitor designed to capture high-accuracy physiological data with a cloud platform that helps transform these data into actionable clinical insights. MultiSense® is a patented medical device that has received multiple awards. MultiSense® has been validated by 6 completed clinical investigations.RDS relies on a talented and international team with deep subject-matter-expertise and a proven track record in the Healthcare and Medical Device sector. At RDS, we all share the same passion for bringing patient pathways to the next level. | $1.1M | Seed | Sep 01, 2023 |  |

10 of 16 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 8 deals together
- [Alsace Business Angels](https://shizune.co/investors/profile/alsace-business-angels) — VC Fund, 3 deals together
- [Finovam Gestion](https://shizune.co/investors/profile/finovam-gestion) — VC Fund, 3 deals together
- [MACSF](https://shizune.co/investors/profile/macsf) — VC Fund, 2 deals together
- [Ademe](https://shizune.co/investors/profile/ademe) — VC Fund, 1 deal together
- [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Medical Device Investors in France](https://shizune.co/investors/medical-device-investors-france)
- [Life Science Investors in France](https://shizune.co/investors/life-science-investors-france)
- [Life Science VC Funds in France](https://shizune.co/investors/life-science-vc-funds-france)

## FAQ

### What does Capital Grand Est invest in?

Capital Grand Est invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Series A stage. Most of the 16 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Capital Grand Est's check size?

Capital Grand Est typically joins rounds of $1.1M–$13M at Seed and $2.6M–$19M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Capital Grand Est participates in.

### How do I contact Capital Grand Est?

Public channels for Capital Grand Est include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Capital Grand Est?

The team at Capital Grand Est includes Stéphane BECKER (Director of Investments). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co